Background {#Sec1}
==========

Breast cancer is the leading US cancer diagnosis in women age 20--45 and is the leading malignancy diagnosed in association with pregnancy in the US \[[@CR1]--[@CR3]\]. Pregnancy results in a complex "'dual effect" on breast cancer risk \[[@CR4]\] with a transient increased risk of breast cancer diagnosis observed during the subsequent postpartum years for all first time mothers \[[@CR5]--[@CR7]\]. This increased risk is reported to last up to 15 years after childbirth regardless of the mother's age \[[@CR5]\]. For women who are under 35 years at first birth, a "cross-over" effect eventually begins to provide long-term protection against breast cancer \[[@CR8]--[@CR10]\]. Thus, the effect of a prior pregnancy on the risk for a young women's breast cancer risk is complex, from initial promotion in the postpartum period to one of protection years to decades later.

A pregnancy-associated breast cancer (PABC) is a breast cancer diagnosed during or a few years subsequent to a recent pregnancy. The specific definition of PABC has varied throughout the literature and this variability in defining PABC has led to conflicting results on the relationship between pregnancy, prior pregnancy and breast cancer outcomes. PABC is often limited to breast cancer diagnosed during pregnancy or within one-year postpartum \[[@CR1], [@CR11]--[@CR16]\]. A number of studies using this definition demonstrate PABC as having inferior prognosis \[[@CR1], [@CR15], [@CR16], [@CR18], [@CR21]\], while two studies identify no increased mortality \[[@CR11], [@CR12]\]. Conversely, five large epidemiologic studies specifically isolating postpartum breast cancers uniformly report poor maternal outcomes associated with postpartum PABC \[[@CR22]--[@CR26]\]. A recently published meta-analysis of 30 PABC studies further suggest that mothers diagnosed postpartum have a significantly worse overall survival (OS) (pHR 1.84, 95 % CI: 1.2--2.65) compared to non-PABC breast cancer cases \[[@CR21]\]. Thus, when PABC is defined as combined pregnant and early postpartum cases, the epidemiologic data on maternal prognosis is inconsistent. However, when cases diagnosed postpartum are examined separately from cases diagnosed during pregnancy, the data demonstrate an increased and potentially prolonged maternal risk of poor outcomes, suggesting an expanded definition of PABC is warranted.

The convention of limiting PABC to pregnant and early postpartum diagnoses originated from studies demonstrating tumor growth promotion by hormonal milieus similar to those occurring during pregnancy \[[@CR10], [@CR27], [@CR28]\]. However, in preclinical models, we reported that during normal, postpartum mammary gland involution, the process where the tissue remodels from a lactation competent to a non-lactational state, the gland acquires several attributes in common with wound-healing and tumor desmoplastic microenvironments \[[@CR29]\]. Furthermore, we have demonstrated that postpartum involution increases the metastatic potential of human tumor cells in xenograft models of postpartum breast cancer \[[@CR30]\]. Based on these observations, we proposed that postpartum involution is a unique biologic event, separate from the effects of pregnancy, that may contribute to the poor prognosis of postpartum breast cancer \[[@CR30]\].

In this study, we characterized young women's breast cancer by luminal A, luminal B, Her2 neu positive, and triple negative biologic subtypes and other clincopathologic features. In addition, we examined the association of distant recurrence (DR) and OS with time since last child birth to delineate the relationship between a postpartum diagnosis and maternal prognosis.

Methods {#Sec2}
=======

A retrospective cohort study was conducted with 619 women age ≤45 years diagnosed with breast cancer during 1981--2011 at University of Colorado Hospital (*n* = 539) and The Shaw Cancer Center in Edwards, CO (*n* = 80). Patient data were abstracted through medical chart review. 71 % of cases are self-reported Caucasian (*n* = 440), 9 % Hispanic (*n* = 56), 4.5 % Black (*n* = 28), and 3.7 % other (*n* = 23). 11.8 % (*n* = 72) chose not to report racial demographic information. All research was approved by the Colorado Multiple Institutional Review Board.

Defining cases by parity status {#Sec3}
-------------------------------

Postpartum breast cancer was defined as cancers diagnosed within five years of a woman's last childbirth (PABC \<5, *n* = 136), and those diagnosed during pregnancy were considered a separate subset of PABC (*n* = 24). All cases in the pregnant subset completed delivery of the co-diagnosed child. Later parous cases were combined according to years between last childbirth and breast cancer diagnosis: parous \>5---\<10 (*n* = 130) and parous ≥10 (*n* = 147). Nulliparous women with no evidence of previous pregnancy were used as the referent population (*n* = 125). Nulliparous women with evidence of incomplete pregnancy were excluded (*n* = 57).

Clinical characterization of young women breast cancer {#Sec4}
------------------------------------------------------

Cases were characterized according to parity grouping (*n* = 562). Clinical stage was defined according to the AJCC Cancer Staging Manual (7th Edition). Luminal A biologic subtype was defined as ER+, PR+, Her2 neu negative; luminal B defined as ER+, PR±, Her2 neu+; Her2 neu+ defined by ER−, PR−, Her2 neu+; and a triple negative defined by ER, PR and Her2 neu all negative .

Statistical analysis {#Sec5}
--------------------

Cohort demographic, clinical, and treatment data are summarized in Table [1](#Tab1){ref-type="table"}. To test for intergroup differences, Chi-square and Fishers Exact Test (categorical variables), and One-Way ANOVA (continuous variables) were used.Table 1Clinical Characterization of UC Young Women's Breast Cancer CohortParity groupNulliparousPABC \<5Parous ≥5 ---\<10Parous ≥10*p* value(*N* = 125)(*N* = 136)(*N* = 130)(*N* = 147)OverallPABC \<5 vs. nulliparousNo. (%)No. (%)No. (%)No. (%)Mean age at diagnosis37.3 ± 5.535.7 ± 5.338.7 ± 4.540.9 ± 3.5\<0.0001^d^\<0.05^d^ Histologic subtype  Ductal109 (87.20)120 (88.24)111 (85.38)119 (80.95)0.09^e^0.54^e^12 (8.16)  Lobular1 (0.80)5 (3.68)10 (7.69)  Ductal + lobular3 (2.40)3 (2.21)5 (3.85)6 (4.08)  Inflammatory2 (1.60)2 (1.47)1 (0.77)5 (3.40)  Other5 (4.00)4 (2.94)1 (0.77)2 (1.36)  Missing5 (4.00)2 (1.47)2 (1.54)3 (2.04) Biologic subtype  Luminal A38 (30.40)52 (38.24)47 (36.15)49 (33.33)0.96^f^0.78^f^  Luminal B18 (14.40)17 (12.50)13 (10.00)18 (12.24)  Her2 neu positive11 (8.80)11 (8.09)12 (9.23)13 (8.84)  Triple negative18 (14.4)20 (14.71)16 (12.31)25 (17.01)  Missing Her2 neu^**a**^28 (22.40)28 (20.59)26 (20.00)32 (21.77)  Missing ER or PR12 (9.60)8 (5.88)16 (12.30)10 (6.80) Estrogen status  ER+77 (61.6)87 (63.9)81 (62.3)83 (56.46)0.37^f^0.48^f^  ER−39 (31.2)37 (27.20)39 (30.0)54 (36.73)  Missing9 (7.2)10 (7.35)10 (7.69)10 (6.80) Histologic grade  Grade I15 (12.00)10 (7.35)14 (10.77)18 (12.24)0.27^f^0.55^f^  Grade II39 (31.20)39 (28.68)39 (30.00)60 (40.82)  Grade III61 (48.80)73 (53.68)63 (48.46)54 (36.73)  Missing10 (8.00)14 (10.29)14 (10.77)15 (10.20) Tumor size  0.1---≤2.0 cm61 (48.80)67 (49.26)49 (37.69)62 (42.18)0.18^f^0.97^f^  \>2.0---≤5.0 cm41 (32.80)44 (32.35)45 (34.62)59 (40.14)  \>5.0 cm14 (11.20)14 (10.29)25 (19.23)20 (13.60)  Missing9 (7.20)11 (8.09)11 (8.46)6 (4.08) Stage  04 (3.20)3 (2.21)5 (3.85)3 (2.04)0.40^f^0.62^f^  I36 (28.80)34 (25.00)27 (20.77)39 (26.53)  II52 (41.60)52 (38.24)57 (43.85)62 (42.18)  III20 (16.00)26 (19.12)31 (23.85)31 (21.09)  IV6 (4.80)12 (8.82)2 (1.54)7 (4.76)  Missing7 (5.60)9 (6.62)8 (6.15)5 (3.40) Lymph node involvement  Positive59 (47.20)76 (55.88)64 (49.23)71 (48.30)0.45^f^0.14^f^  Negative64 (51.20)57 (41.91)65 (50.00)72 (48.98)  Missing2 (1.60)3 (2.21)1 (0.77)4 (2.72) Lymphovascular invasion  Present28 (22.40)40 (29.41)40 (30.77)57 (38.78)0.21^f^0.15^f^  Absent55 (44.00)50 (36.76)53 (40.77)60 (40.82)  Missing42 (33.60)46 (33.82)37 (28.46)30 (20.41) Surgery type^b^  No surgery0 (0)3 (2.5)1 (0.88)3 (2.3)\<0.0001^f^\<0.0001^f^  Local excision^c^0 (0)0 (0)1 (0.88)1 (0.8)  Lumpectomy51 (46.8)27 (22.9)32 (28.0)36 (28.1)  Unilateral mastectomy25 (22.9)37 (31.4)48 (42.1)51 (39.8)  Bilateral mastectomy15 (13.8)37 (31.4)17 (14.9)11 (8.6)  Missing18 (16.5)14 (11.8)15 (13.2)26 (20.3) Chemotherapy^b^  Yes66 (60.6)79 (67.0)71 (62.3)71 (55.5)0.55^f^0.17^f^  No22 (20.2)16 (13.6)21 (18.4)22 (17.2)  Missing21 (19.2)23 (19.4)22 (19.3)35(27.3) Radiation therapy^b^  Yes57 (52.2)51 (43.2)61 (53.5)50 (39.0)0.07^f^0.22^f^  No29 (26.6)38 (32.2)26 (22.8)44 (34.4)  Missing23 (21.1)29 (24.6)27 (23.7)34 (26.6)^a^Missing Her2 neu data, reflecting unavailable Her2 neu staining or FISH analysis at diagnosis, was evenly distributed across parity groups and thus is not anticipated to confound results^b^Treatment data for cases diagnosed at the University of Colorado Hospital (*n* = 469)---nulliparous (*n* = 109), PABC \<5 (*N*=118), Parous ≥5---\<10 (*n* = 114); Parous ≥10 (*n* = 128). Treatment data unavailable for cases diagnosed at The Shaw Cancer Center (*n* = 80); treatment data for cases diagnosed during pregnancy are included in supplemental Table 7^c^Primary unknown^d^One Way Anova with Tukey's Multiple Comparisons Test^e^Fisher's Exact Test^f^χ^2^ Test

Estimating risk of distant recurrence (DR) and overall survival (OS) {#Sec6}
--------------------------------------------------------------------

A DR was defined as the presentation of breast cancer metastasis following completed primary breast cancer staging. Cases with no evidence of DR and cases alive at the end of followup were censored at the date of last contact. To better power our analysis, cases diagnosed ≥5 years following last childbirth were collapsed. Nulliparous cases with evidence of prior pregnancy (*n* = 57) and pregnant cases (*n* = 24) were excluded from the outcomes analyses. Kaplan--Meier curves were created to determined crude differences in DR and OS. Cox proportional multivariate regression models were performed to obtain adjusted risk estimates for DR, OS, hazard ratios and 95 % confidence intervals. Cases missing followup data (*n* = 52), model covariates (*n* = 189), declining treatment (*n* = 4), or having multiple primary breast cancers (*n* = 6), and cases stage 0 (*n* = 15) and stage IV (*n* = 27) were excluded. After these exclusions, 326 cases were analyzed for DR. Stage IV cases were included in the OS analysis to reflect true population outcomes, resulting in 334 cases available for the OS analysis. Stage, biologic subtype, prior local recurrence, and year of diagnosis were included in the final multivariate model of DR. Stage, biologic subtype, and year of diagnosis were included in the final multivariate model of OS. Age at diagnosis was not significantly different between groups and was not included in the multivariate models.

All statistics were performed using SAS 9.2. A *p* value of ≤0.05 was considered statistically significant.

Results {#Sec7}
=======

Table [1](#Tab1){ref-type="table"} shows the clinical characterization of our Colorado young women's breast cancer cohort. We did not observe a significant difference in histologic subtype across parity groups (*p* = 0.09). While there was a slightly higher frequency of lobular carcinoma in all parous groups compared to nulliparous, this result was not significant. Similarly, we did not detect a significant difference in histologic grade (*p* = 0.27), tumor size (*p* = 0.18), clinical stage (*p* = 0.40), or nodal involvement (*p* = 0.45) between parity groups. While all postpartum groups demonstrated an increased frequency of lymphovascular invasion compared to nulliparous, these differences were not significant. We did not observe differences in chemotherapy and radiation treatment modalities between parity groups. However, compared to PABC \<5 cases, nulliparous cases more often underwent breast conservation therapy (22.9 vs. 46.8 %), while PABC \<5 cases received mastectomy more frequently compared to nulliparous cases (*p* \< 0.0001) (Table [1](#Tab1){ref-type="table"}).

To evaluate the effect of prior pregnancy on maternal outcomes, we examined the risk of DR and OS. Postpartum PABC cases demonstrated a higher five-year DR probability (31.1 %) compared to nulliparous cases (14.8 %) (Fig. [1](#Fig1){ref-type="fig"}a, b) and had a significant 2.8 times higher risk of DR (HR 2.80, 95 % CI: 1.12--6.57) compared to nulliparous cases (Table [2](#Tab2){ref-type="table"}). The multivariate DR risk model demonstrated an increased metastatic potential associated with a breast cancer diagnosed within five-years postpartum, adjusting for stage at diagnosis, biologic subtype, prior local recurrence, and year of diagnosis.Fig. 1**a** Unadjusted probability of distant recurrence in PABC \<5, ≥5, and nulliparous cases demonstrates an increased risk of distant recurrence in postpartum PABC. **b** Adjusted probability of distance recurrence in PABC \<5, ≥5, and nulliparous cases adjusted for biologic subtype, clinical stage, year of diagnosis, and local recurrence. The adjusted recurrence probability function based on the Cox model was generated for each subject. **c** Unadjusted overall survival probability in PABC \<5, ≥5 and nulliparous cases demonstrates an increased risk of death in postpartum PABC. **d** Adjusted overall survival probability in PABC \<5, ≥5, and nulliparous cases adjusted for biologic subtype, clinical stage, and year of diagnosis. The adjusted survival function based on the Cox model was generated for each subjectTable 2Adjusted risk estimates of distant recurrenceMultivariate analysisParity group^a^Number of casesAdjusted HR^b,c^95 % CI*p*5-Year distant recurrence probability (%)PABC \<5*N* = 842.801.12--6.570.0231.3 Parous ≥5*N* = 1681.010.48--2.150.9719.9Nulliparous*N* = 741.0----14.8Hazard ratios and 95 % confidence intervals for all covariates included in the final model are described in Table 6 in the supplemental material. Clinical characteristics of the collapsed Parous ≥5 group can be viewed in Table 8 in the supplemental materialParous ≥5, cases diagnosed five years or later from last childbirth^a^PABC \<5 cases had a mean followup time of 2.7 ± 2.7 years. Mean followup time for nulliparous was 3.2 ± 3.2 years and 3.5 ± 3.6 years for cases diagnosed ≥5^b^Adjusted for tumor biologic subtype, clinical stage, year of diagnosis, and local recurrence^c^Histologic subtype and grade were not univariately significant and were thus not included in the final multivariate models

PABC \<5 cases demonstrated a crude lower five-year OS probability (65.8 %) compared to nulliparous cases (98.0 %) (Fig. [1](#Fig1){ref-type="fig"}c, d). The relatively high five-year OS in this nulliparous cohort mirrors previously published data \[[@CR18]\]. After adjusting for stage, biologic subtype, and year of diagnosis, PABC \<5 cases had a significant 2.7 times greater risk of death compared to nulliparous cases (HR 2.65, 95 % CI: 1.09--6.42) (Table [3](#Tab3){ref-type="table"}).Table 3Adjusted risk estimates of overall survivalMultivariate analysisParity group^a^Number of casesAdjusted HR^b,c^95 % CI*p*5-Year survival (%)PABC \<5*N* = 862.651.09--6.420.0365.8Parous ≥5*N* = 1721.520.71--3.280.2877.5Nulliparous*N* = 761.0----98.0Hazard ratios and 95 % confidence intervals for all covariates included in the final model are described in Table 7 in the supplemental material. Clinical characteristics of the collapsed Parous ≥5 group can be viewed in Table 8 in the supplemental materialParous ≥5 cases diagnosed five years or later from last childbirth^a^PABC \<5 cases had a mean followup time of 3.0 ± 2.9 years. Mean followup time for nulliparous was 3.6 ± 3.6 years and 3.9 ± 3.7 years for cases diagnosed ≥5^b^Adjusted for tumor biologic subtype, clinical stage, and year of diagnosis^c^Histologic subtype and grade were not univariately significant and were thus not included in the final multivariate models

To evaluate clinical outcomes for cases diagnosed ≥5-years postpartum, we compressed later parity cohorts to increase statistical power (Supplemental Table 8). Our data suggest that cases diagnosed ≥5-years postpartum may have a prognosis intermediate to PABC \<5 and nulliparous cases (Fig. [1](#Fig1){ref-type="fig"}a--d). These cases demonstrated a crude 19.9 % five-year DR probability and crude 77.5 % five-year OS probability. Cases diagnosed ≥5 had a significantly lower DR risk compared to PABC \<5 cases (HR 0.36; 95 % CI: 0.18--0.75) (Table [2](#Tab2){ref-type="table"}). However, compared to nulliparous cases, cases ≥5 postpartum showed a trend toward higher risk of death (HR 1.52; 95 % CI: 0.71--3.28), but this result did not meet significance (Table [3](#Tab3){ref-type="table"}). Age at diagnosis was examined as both a continuous and categorical variable (\<35 or ≥35, or \<40 or ≥40) in the univariate DR and OS models, but did not reach statistical criterion for inclusion in the final models. Hazard ratios for the final multivariate models are included in the supplemental material (Table 6, Table 7).

To investigate whether PABC may be two distinct subsets, based on patient outcomes, we combined cases based on previously published definitions \[[@CR1], [@CR11], [@CR12], [@CR15], [@CR16], [@CR18]\], and grouped pregnant cases and cases diagnosed ≤1 year postpartum as in the "PABC group." Nulliparous and/or parous women diagnosed \>1 year postpartum were combined to comprise the "non-PABC" controls, mirroring methods used in two recent studies reporting negative results \[[@CR11], [@CR12]\]. When grouped this way, we also did not observe a significant difference in OS between "PABC" and "non-PABC" cases (Table [4](#Tab4){ref-type="table"}). To examine if the poor prognosis observed in our PABC \<5 cohort is driven by cases diagnosed early postpartum (≤1), we examined the adjusted OS in postpartum ≤1 compared to postpartum \>1---5. We did not observe a significantly lower OS in postpartum cases ≤1 compared to the later postpartum cases (*p* = 0.51). Further, when we examined the crude number of deaths broken down by years postpartum at diagnosis \[≤1, \>1---≤2, \>2---≤3,\>3---≤4, and\>4---≤5 years\], we did not observe a skewing of deaths to the earlier postpartum time points (Fig. [2](#Fig2){ref-type="fig"}).Table 4Adjusted risk estimate of overall survival using published definitions of PABC and control cohortsParity groupAdjusted HR^a^95 % CI*p*PABC ≤1 (*n* = 33)0.780.29--2.110.63Non-PABC (A) (*n* = 318)1.0----PABC ≤1 (*n* = 33)0.770.28--2.080.60Non-PABC (B) (*n* = 242)1.0----PABC ≤1, cases diagnosed during pregnancy or up to one-year postpartum; Non-PABC (A), nulliparous cases and parous cases diagnosed \>1 year from last childbirth. Non-PABC (B) ^,^parous cases diagnosed \>1 year from last childbirth (nulliparous excluded)^a^Adjusted for tumor biologic subtype, clinical stage and year of diagnosisFig. 2Crude mortality broken out into years between last childbirth and breast cancer diagnosis shows increased risk continues 3--5 years postpartum

Cases diagnosed during pregnancy showed a high frequency of ductal carcinoma (91.7 %) and poorly differentiated tumors (70.8 %). Over half of these pregnant cases had involved lymph nodes (62.5 %) and 42 % were diagnosed with late stage disease. Luminal A (20 %), Luminal B (20 %), Her2 neu+ (20 %), and triple negative (25 %) biologic subtypes were present in almost equal frequencies (Table [5](#Tab5){ref-type="table"}). However, due to the small number of pregnant cases (*n* = 24), we did not test for a significant enrichment in these clinical characteristics over non-pregnant cases. Further, due to the small sample size and short followup time, we did not analyze maternal outcomes specific to diagnosis during pregnancy.Table 5Clinical characteristics of cases diagnosed during pregnancy (*n* = 24)*N* (%)Histologic subtype Ductal22 (91.7) Lobular1 (4.16) Missing1 (4.16)Histologic grade Grade I0 (0) Grade II5 (20.8) Grade III17 (70.8) Missing2 (8.33)Lymph node involvement Positive15 (62.50) Negative8 (33.33) Missing1 (4.16)Stage 00 (0) I5 (20.83) II9 (37.50) III6 (25.00) IV4 (16.67)Biologic subtype Luminal A5 (20.80) Luminal B5 (20.80) Her2 neu positive5 (20.80) Triple negative6 (25.00) Missing3 (12.6)Lymphovascular invasion Present6 (25.00) Absent9 (37.50) Missing9 (37.50)Tumor size 0.1---≤2.0 cm9 (37.50) \>2.0---≤5.0 cm9 (37.50) \>5.0 cm3 (12.50) Missing3 (12.50)

In summary, these data demonstrate poor prognosis in breast cancer patients diagnosed within five years of a pregnancy and suggest an intermediate risk in women diagnosed beyond five-years postpartum. When we apply these definitions to this Colorado cohort, we identify of a large subset (29 %) of young breast cancer cases with a potential high risk of DR and death due to recent pregnancy (postpartum \<5 years) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Expanding the definition of PABC as cases diagnosed within five-years postpartum, we demonstrate 29 % of cases have an increased risk for poor prognosis. Only 10 % are considered PABC when defined as cases pregnant and postpartum up to one year

Discussion {#Sec8}
==========

Our results demonstrate that a breast cancer diagnosed within five-years postpartum has a significant 2.8 times higher risk for metastasis and a 2.7 times higher mortality risk compared to nulliparous cases. Our data further shows that a postpartum breast cancer diagnosis is an independent risk factor for recurrence and death. In our cohort, the increased risk of death imparted by a postpartum diagnosis was higher when compared with previous published studies \[[@CR22]--[@CR24], [@CR26], [@CR31]\]. A strength of our study is the ability to include clinical and pathologic characteristics known to affect prognosis into our adjusted outcomes analysis for the effect of pregnancy on recurrence and death. As such, one potential reason for our higher risk differences may be the absence of clinical characteristics in prior PABC studies and thus the inability to report adjusted risk estimates \[[@CR23], [@CR26], [@CR31]\].

In our cohort, parous women diagnosed ≥5 years following last childbirth trended toward a prognosis intermediate to PABC \<5 and nulliparous women. We propose that the period of postpartum risk may persist to at least five-years postpartum as demonstrated by these data, which are likewise supported by previously published studies highlighting the postpartum window of risk \[[@CR22]--[@CR26], [@CR31]\]. In two of these population-based studies, poor outcomes were observed in women diagnosed up to eight years after childbirth \[[@CR23]\], as well as a recent study demonstrated peak mortality in women diagnosed postpartum and persisting up to 10-years post-diagnosis \[[@CR26]\]. We intentionally looked at our data by individual number of years postpartum to identify if an early "cutoff" of increased risk existed and found that the postpartum risk of recurrence and death is not limited to the first or second-year postpartum, as some studies previously suggested \[[@CR1], [@CR15], [@CR16], [@CR18]\]. At present, we cannot delineate the exact outer limit of this postpartum timeframe which may influence poor maternal prognosis. However, further study in larger cohorts with complete clinical data is necessary to better define the true extent and clinical implications of this interaction between postpartum diagnosis and increased risk of breast cancer recurrence and death.

Another aim of our study was to identify a methodological reason for the disparate results in prior PABC studies. An important distinction of our study is the utilization of rigorously defined parity status. Prior studies have combined pregnant and early postpartum cases as PABC and utilized various referent populations. Six published studies reporting outcomes included parous women diagnosed within seven to 24 months of last childbirth in the non-PABC "control" group---four studies identify an increased risk for PABC cases \[[@CR1], [@CR15], [@CR16], [@CR18]\] and two report no increase in risk \[[@CR11], [@CR12]\]. Of the four studies identifying an increased risk for PABC cases, three used a PABC cohort comprised of predominately early postpartum cases \[[@CR1], [@CR15], [@CR18]\]. One study used a PABC cohort comprised of 40 % early postpartum and 60 % pregnant cases \[[@CR16]\].When we applied similar definitions of PABC \[pregnant and up to 1 year postpartum\] and non-PABC \[nulliparous and beyond 1 year postpartum\] to our cohort, we also did not observed a significant increased risk associated with PABC (Table [4](#Tab4){ref-type="table"}). We believe the inclusion of high-risk postpartum cases in the non-PABC control population blurs the true risk associated with a postpartum and nulliparous diagnosis. While our numbers of combined pregnant and \<1 year postpartum are small, we provide evidence for the first time that the definition of the PABC and the nulliparous groups may obscure the risk of metastasis and death in postpartum breast cancer.

Currently, it is challenging to explain the conflicting data provided by these numerous studies to clarify the potential individual contributions of the pregnant and postpartum settings on breast cancer outcomes. Studies with pregnancy-specific data often include cases definitively treated during pregnancy, cases with early trimester terminations, and cases diagnosed during pregnancy, but treated postpartum \[[@CR12], [@CR18], [@CR32]\] within the pregnant cohort. The impact of these clinical factors on breast cancer outcomes for women diagnosed during pregnancy is unknown. Furthermore, studies examining pregnant cases treated with definitive intent during pregnancy and concomitant maintenance of the pregnancy demonstrate equivalent outcomes to age-matched, stage-matched, non-pregnant controls \[[@CR33], [@CR34]\]. Our pregnancy cohort all completed delivery and received surgery and/or chemotherapy during pregnancy. We report a higher percentage of Her2 neu and triple negative cases over other subtypes which are unique to cases diagnosed during pregnancy (Table [5](#Tab5){ref-type="table"}). A similar increase of triple negative associated with diagnosis during pregnancy was recently reported \[[@CR17]\]. However, the size of our pregnant cohort does not permit further characterization, conclusions, or outcomes investigation at this time. Currently, others are making important efforts to build a large pregnant breast cancer registry to provide the resources necessary to help address these questions \[[@CR2]\].

Our observation of equal presentation of biologic subtypes between nulliparous, PABC \<5, and later parous cases contrasts prior reports \[[@CR1], [@CR12], [@CR13], [@CR16], [@CR17]\] and may reflect underlying differences in sociodemographic and lifestyle factors in this dominantly Caucasian, single-state cohort. Importantly, it may also reflect a difference in outcomes depending on the definition of PABC. Previous studies that reported on combined pregnant and early postpartum cancers found an "aggressive phenotype," characterized by advanced clinical stage, larger tumor size, increased nodal involvement, and higher histologic grade \[[@CR1], [@CR11], [@CR12], [@CR16]\]. Moreover, compared to non-PABC cases, various studies reported these combined pregnant and early postpartum tumors are marked by reduced estrogen and progesterone receptor positivity \[[@CR1], [@CR12], [@CR13], [@CR16]\], as well as higher frequency of Her2 neu positivity but not specifically the triple negative subtype \[[@CR13], [@CR17]\]. When early postpartum and pregnant cases were evaluated independently, there was contradictory data reported on the clinicopathologic features of these pregnant and postpartum subsets \[[@CR12], [@CR13], [@CR17]--[@CR20]\]. Moreover, a recent PABC publication concluded triple negative tumors were more likely to be diagnosed within two-years postpartum \[[@CR17]\]. However, in that study, when the pregnant (*n* = 8) cases were separated from the exclusively postpartum cases (*n* = 30), there was no association of triple negative tumors with a postpartum diagnosis \[[@CR17]\]. In summary, we believe it is important to recognize that the characteristics of breast cancers diagnosed during pregnancy or postpartum may differ based on PABC definition, as well as due to potential confounders such as race or size of the cohort. The causal relationships between concurrent or prior pregnancy and tumor characteristics at diagnosis are not fully understood and beyond the scope of this report. However, as our data demonstrate, tumor characteristics alone do not account for the poorer prognosis of postpartum breast cancer and identification of the drivers for this increased risk of postpartum breast cancers are necessary to improve clinical outcomes.

To our knowledge, our study is unique in providing a contemporary comparison of outcomes between exclusively nulliparous and postpartum young women's breast cancer cohorts. The favorable outcomes of our nulliparous group, compared to prior studies with similar cohorts, may reflect a period effect as breast cancer treatment has improved significantly over time \[[@CR24], [@CR31], [@CR32]\]. Our data demonstrate a striking 2.7 higher risk of death for women diagnosed within five-years postpartum compared to nulliparous, after adjusting for biologic subtype, clinical stage, and year of diagnosis. Our research program has identified postpartum breast involution as being promotional to tumor growth, invasion, and metastasis in preclinical models \[[@CR30]\]. Similar tumor promotional attributes have been identified in human breast involution \[[@CR30], [@CR35]\], as recently reviewed \[[@CR36]\]. Therefore, we hypothesized that human postpartum breast cancer has poorer prognosis that is not solely explained by an enrichment of traditional poor prognostic factors that are tumor cell centric \[[@CR8], [@CR10], [@CR30], [@CR35]\]. While our results do not definitively prove the role of involution as etiologic for poorer postpartum outcomes, it does support the potential that breast involution imparts a unique tumor microenvironment as a mechanism for this increased risk \[[@CR8], [@CR36]\]. Further research in human cohorts on the interaction of pregnancy and subsequent breast cancer will need to include additional potential confounders, such as diversification of race, number of prior pregnancies with age at first pregnancy and intervals between, lactation data, gene mutation status, and detailed family history.

The under recognition of PABC and its impact on maternal outcomes is likely an unintended consequence of the variable definitions of the disease and the conflicting outcomes data. We demonstrate that limiting the definition of PABC as cases diagnosed during or within one year of a completed pregnancy translate into a low PABC incidence (10 %) in our Colorado cohort. Expanding the definition of PABC to within five-years postpartum increases this incidence to 29 % for women diagnosed ≤45 years. This higher PABC incidence is substantiated in a recently published study of young women's breast cancer where 35 % of cases were diagnosed within five-years postpartum \[[@CR17]\]. In addition, PABC incidence could be as high as 53.0 % or more of young women's breast cancer if the trend in later parous groups (≥5 and \<10 years postpartum) becomes significant in analyses of larger cohorts with longer followup (Fig. [3](#Fig3){ref-type="fig"}). If the distribution of postpartum PABC in our cohort is nationally representative, over a five-year period we would expect approximately 34,000 incident invasive breast cancer cases attributable to high risk postpartum PABC (PABC \<5), and 6,900 incident diagnoses annually \[[@CR37], [@CR38]\].

Pregnancy ubiquitously proceeds involution and has its own significant biologic programs that influence breast cancers diagnosed both ante- and postpartum \[[@CR8], [@CR36]\]. Postpartum breast involution is a biologically unique event that is also emerging as a potential risk factor for premenopausal breast cancer \[[@CR8], [@CR30], [@CR36]\]. Understanding the differences between breast cancers diagnosed during pregnancy and postpartum would better permit the translation of informative data from basic science and epidemiologic studies into the clinical care of young women's breast cancer. Therefore, we propose defining PABC as two distinct subsets---cases diagnosed during pregnancy and cases diagnosed postpartum---to facilitate clarity in the PABC field.
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